In the nuclear substudy of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, Shaw et al 1 showed that adding percutaneous coronary intervention (PCI) to optimal medical therapy (OMT) resulted in a greater reduction in ischemia than did OMT alone. Moreover, they also found that the magnitude of residual ischemia on follow-up was proportional to the risk of death or myocardial infarction, and a Ն5% reduction in ischemia was associated with a significant reduction in risk. At adjusted analysis, the authors failed to find an independent treatment effect on these results.
To the Editor:
In the nuclear substudy of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, Shaw et al 1 showed that adding percutaneous coronary intervention (PCI) to optimal medical therapy (OMT) resulted in a greater reduction in ischemia than did OMT alone. Moreover, they also found that the magnitude of residual ischemia on follow-up was proportional to the risk of death or myocardial infarction, and a Ն5% reduction in ischemia was associated with a significant reduction in risk. At adjusted analysis, the authors failed to find an independent treatment effect on these results.
A closer look at their report suggests that some points deserve further comments to avoid misleading readers and to clarify the clinical implications of the study. At baseline, moderate-to-severe ischemia at myocardial perfusion single photon emission computed tomography was present only in one third of cases. At follow-up, although a higher percentage of the patients in the PCIϩOMT group had no inducible ischemia (15% versus 9%; Pϭ0.06), as few as 33% of the PCIϩOMT patients had a significant reduction in ischemia Ն5% at myocardial perfusion single photon emission computed tomography compared with 20% in OMT patients. This point is evident if we consider that two third of the patients had at least 2-coronary vessel disease and that for patients randomized to PCI, no data exist on the rate of complete revascularization. In patients with stable multivessel coronary artery disease, the identification of the target lesion may be troublesome. In the study by Shaw et al, 1 the rate of patients free from angina was not significantly different between the PCIϩOMT and OMT groups at follow-up. Maintaining the relationship between event-free survival and reduction in ischemic myocardium, we think that the failure to appreciate a striking treatment effect of PCIϩOMT in reducing cumulative event freesurvival compared with OMT might be related to both the relative low ischemic burden of the population at baseline as well as to incomplete revascularization at the time of PCI. We wonder whether OMT could remain "not inferior" to complete revascularization by PCI even at higher levels of ischemic burden.
